J.ophthalmol.(Ukraine).2018;1:13-18.

https://doi.org/10.31288/oftalmolzh201811318


Comparison of morphometric changes in the chorioretinal complex after anti-VEGF treatment in patients with pathologic myopia versus those with neovascular age-related macular degeneration

O.M. Blavatska 1, T.B. Kustryn 2, A.R. Korol 2, Dr Sc (Med)

1  Danylo Halytsky Lviv National Medical University;

Lviv (Ukraine)

2  Filatov Institute of Eye Diseases and Tissue Therapy;

Odessa (Ukraine)

E-mail: syannya@rambler.ru, laserfilatova@gmail.com         

TO CITE THIS ARTICLE: Blavatska OM, Kustryn TB, Korol AR. Comparison of morphometric changes in the chorioretinal complex after anti-VEGF treatment in patients with pathologic myopia versus those with neovascular age-related macular degeneration. J.ophthalmol.(Ukraine).2018;1:13-8. https://doi.org/10.31288/oftalmolzh201811318

       

Purpose: To compare morphometric changes in the chorioretinal complex after anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with pathologic myopia (PM)-related choroidal neovascularization (CNV) versus those with age-related macular degeneration (AMD)-related CNV.

Materials and Methods: This was a prospective comparative uncontrolled cohort study involving 156 patients (169 eyes) with subfoveal CNV. Of these, 82 (85 eyes) had pathologic PM-related CNV, and 74 (85 eyes) had AMD-related CNV. Patients with AMD underwent a treatment regimen of three mandatory monthly 0.5-mg (0.05-mL) intravitreal ranibizumab injections followed by pro re nata (PRN) dosing according to re-treatment criteria. Patients with PM underwent a treatment regimen of two mandatory monthly 0.5-mg (0.05-mL) intravitreal ranibizumab injections or 2-mg (0.05-mL) intravitreal aflibercept injections followed by PRN dosing according to re-treatment criteria. Primary outcomes were central retinal thickness (CRT) and CNV thickness at month 12. Secondary outcomes included best-corrected visual acuity (BCVA) and number of injections at month 12.

Results: At month 12, (1) mean OCT-based CRT in AMD and PM groups decreased from 349 μm to 258 μm (P = 0.00), and from 306 μm to 228 μm (P = 0.00), respectively, and (2) mean CNV thickness in AMD and PM groups decreased from 183 μm to 108 μm (P = 0.00), and from 229 μm to 173 μm (P = 0.00), respectively. In addition, mean (SD) BCVA in the AMD group improved from 0.25 (0.23) at baseline to 0.33 (0.29), whereas that in the PM group improved from 0.17 (0.11) to 0.35 (0.19). The mean number of anti-VEGF injections was 5.4 (2.1) and 2.2 (0.6) for the AMD and PM groups, respectively, with the between-group difference being statistically significant (P = 0.00).

Conclusions: Decrease in central retinal thickness and improvements in visual acuity after anti-VEGF treatment for AMD-related subfoveal CNV were similar to those after anti-VEGF treatment for PM-related subfoveal CNV. At month 12, percent decreases in CNV thickness compared to baseline were 26% and 41% for anti-VEGF treated patients with AMD-related and PM-related subfoveal CNV, respectively. Patients with AMD-related CNV required, on average, 3 more anti-VEGF injections than those with PM-related CNV.

Keywords: pathologic myopia, age-related macular degeneration, choroidal neovascularization, anti-VEGF agents

 

References

  1. Cohen SY, Laroche A, Leguen Y. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103:1241–44.
    Crossref   Pubmed
  2. Freund KB, Yannuzzi LA, Sorenson JA. Age-related Macular Degeneration and Choroidal Neovascularization. Am J Ophthalmol. 1993 Jun 15;115(6):786–91.
    Crossref   Pubmed
  3. Green WR, Wilson DJ. Choroidal Neovascularization. Ophthalmology.  1986;93:1169–76.
    Crossref   Pubmed
  4. Grossniklaus HE, Green WR. Choroidal Neovascularization. Am J Ophthalmol. 2004;137:496–503.
    Crossref   Pubmed
  5. Blinder KJ, Blumenkranz MS, Bressler NM et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—VIP report no 3. Ophthalmology. 2003;110:667–73.
    Crossref   Pubmed
  6. Klein R, Klein BE, Tomany SC et al. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2002;109:1767–9.
    Crossref   Pubmed
  7. Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularization in pathologic myopia. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004765.
  8. Brown DM, Michels M, Kaiser PK et al, ANCHOR Study Group. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study. Ophthalmology. 2009;116:57–65.
    Crossref   Pubmed
  9. Heier JS, Brown DM, Chong V et al. VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–48.
    Crossref   Pubmed
  10. Regillo CD, Brown DM, Abraham P et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239–48.
    Crossref   Pubmed
  11. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2006;355(14):1419–31.
    Crossref   Pubmed
  12. Tufail A, Narendran N, Patel PJ et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120(9):1944–5.
    Crossref   Pubmed
  13. Wolf S, Balciuniene VJ, Laganovska G et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.  Ophthalmology. 2014;121:682–92.
    Crossref   Pubmed
  14. Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR study. Ophthalmology. 2015;122(6):1220-7.
    Crossref   Pubmed
  15. Blavatska OM, Kustryn TB, Korol AR. Comparison of intravitreal ranibizumab and aflibercept in patients with choroidal neovascularization in pathologic myopia. J.ophthalmol.(Ukraine).2017;5:34-38.
    Crossref 
  16. Cha DM, Kim TW, Heo JW et al. Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study. BMC Ophthalmol. 2014;14:69.
    Crossref   Pubmed
  17. Ozdek S., Hondur A., Gurelik G., et al. Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV. Int Ophthalmol. 2005 Aug-Oct;26(4-5):127-33.
    Crossref   Pubmed